Using imaging and blood tests to track cancer treatment response and predict progression
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy
This study is looking at how using blood tests that check for cancer DNA along with regular scans can help doctors see if cancer treatments are working sooner, so patients getting new cancer therapies can get the best care possible.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10889983 on NIH RePORTER |
What this research studies
This research investigates how combining imaging techniques with blood tests that analyze circulating tumor DNA (ctDNA) can provide a more accurate assessment of treatment effectiveness in cancer patients. By monitoring changes in ctDNA levels alongside traditional imaging methods, the study aims to identify treatment success or failure earlier than current methods allow. The approach utilizes advanced sequencing technology to detect genetic alterations in tumors, which can inform targeted therapy decisions. Patients undergoing novel cancer therapies may benefit from this integrated monitoring strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who are receiving targeted therapies.
Not a fit: Patients not undergoing targeted cancer therapies or those with non-cancerous conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more timely and precise adjustments in cancer treatment, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results using similar approaches to monitor treatment response in cancer patients, indicating potential for success in this study.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Berger, Michael F. — Sloan-Kettering Inst Can Research
- Study coordinator: Berger, Michael F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.